UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 27

of 'Clinical features, evaluation, and treatment of retroperitoneal soft tissue sarcoma'

27
TI
Adult soft tissue sarcoma local recurrence after adjuvant treatment without resection of core needle biopsy tract.
AU
Binitie O, Tejiram S, Conway S, Cheong D, Temple HT, Letson GD
SO
Clin Orthop Relat Res. 2013 Mar;471(3):891-8.
 
BACKGROUND: Core needle biopsies of sarcomas allow a diagnosis in a high percentage of patients with few complications. However, it is unclear whether the tract needs to be excised to prevent recurrences.
QUESTIONS/PURPOSES: We therefore determined the rates of recurrence and metastases in patients with Stage III extremity sarcomas, who underwent wide local resection without excision of the needle tract and also received adjuvant treatment.
METHODS: We retrospectively reviewed 59 adult patients with deep, larger than 5 cm, high-grade soft tissue sarcomas of the upper or lower extremity treated between January 1999 and April 2009. All the patients underwent a core needle biopsy. Resection was performed with wide margins. The biopsy tract was not resected during the definitive surgery. Fifty-seven patients (97%) received preoperative and/or postoperative radiation, whereas 49 patients (83%) received chemotherapy. Local recurrence and distant recurrence rates were determined. The minimum followup was 24 months (median, 56 months; range, 24-122 months).
RESULTS: The local recurrence rate was 9%. Fifteen patients (25%) developed metastasis after diagnosis. Seven of the 59 patients (12%) had microscopic positive margins at resection.
CONCLUSIONS: Our data demonstrate no increase in local recurrence rates or rates of metastatic disease compared with previously published studies when resection of the core biopsy tract was not performed.
LEVEL OF EVIDENCE: Level IV, therapeutic study. See the Guidelines for Authors for a complete description of levels of evidence.
AD
H. Lee Moffitt Cancer Center&Research Institute, Sarcoma Program, 12902 Magnolia Drive, Tampa, FL 33612, USA. odionb@gmail.com
PMID